LakeShore Biopharma Co., Ltd (LSB)
USD 2.45
(-3.22%)
USD 2.45
(-3.22%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | -295.22 Million | -182.46 Million | -613.22 Thousand | -246.61 Million |
| Net Income | -433.46 Million | -145.47 Million | -545.72 Thousand | -191.82 Million |
| Depreciation & Amortization | 42.18 Million | 36.68 Million | 31.15 Million | 27.9 Million |
| Deferred income taxes | -21.72 Million | 1.13 Million | 4.93 Million | 17.45 Million |
| Stock-based compensation | 9.78 Million | 3.5 Million | 7.76 Million | 76.75 Million |
| Change in working capital | -45.78 Million | -92.74 Million | -64.04 Thousand | -186.68 Million |
| Other non-cash items | 4.77 Million | 4.42 Million | -3452.00 | 2.23 Million |
| Investing Cash Flow | -44.25 Million | -56.98 Million | -200 Million | -104.23 Million |
| Investments in PPE | -44.25 Million | -57.04 Million | -298.93 Million | -104.88 Million |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | -200 Million | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | - | - | - | - |
| Financing Cash Flow | 205.26 Million | 317.44 Million | 201.49 Million | 739.25 Million |
| Debt repayment | -78.93 Million | -100.87 Million | -364.55 Million | -8.25 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 284.19 Million | - | 201.85 Million | 1.58 Million |
| Other Financing Activities | - | 216.57 Million | -361.02 Thousand | - |
| Accounts receivables | 13.9 Million | -165.24 Million | -99.13 Million | -220.73 Million |
| Accounts payables | -12.66 Million | 49.62 Million | 14.42 Million | -4.42 Million |
| Inventory | -86.26 Million | -18.15 Million | -89.45 Million | -68.72 Million |
| Other working capital | -3.6 Million | -6.44 Million | -64.04 Thousand | -44.29 Thousand |
| Cash at beginning of period | 370.36 Million | 271.06 Million | 390.45 Million | 2.05 Million |
| Cash at end of period | 246.55 Million | 370.36 Million | 885.19 Thousand | 390.45 Million |
| Capital Expenditure | -44.25 Million | -57.04 Million | -298.93 Million | -104.88 Million |
| Effect of forex changes on cash | 10.4 Million | 21.3 Million | -11.47 Million | -2674.00 |
| Net cash flow / Change in cash | -123.81 Million | 99.3 Million | -389.57 Million | 388.4 Million |
| Free Cash Flow | -339.48 Million | -239.51 Million | -299.54 Million | -351.49 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -433.46 Million | -25.09 Million | -10.95 Million | -14.37 Million | -9.58 Million | -145.47 Million |
| Depreciation & Amortization | 42.18 Million | - | - | - | - | 36.68 Million |
| Deferred income taxes | -21.72 Million | - | - | - | - | 1.13 Million |
| Stock-based compensation | 9.78 Million | 1.35 Million | - | - | - | 3.5 Million |
| Change in working capital | -45.78 Million | - | - | - | - | -92.74 Million |
| Other non-cash items | 4.77 Million | 23.73 Million | 10.95 Million | 14.37 Million | 9.58 Million | 4.42 Million |
| Investing Cash Flow | -44.25 Million | - | - | - | - | -56.98 Million |
| Investments in PPE | -44.25 Million | - | - | - | - | -57.04 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 205.26 Million | - | - | - | - | 317.44 Million |
| Debt repayment | -78.93 Million | - | - | - | - | -100.87 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 284.19 Million | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | 216.57 Million |
| Accounts receivables | 13.9 Million | - | - | - | - | -165.24 Million |
| Accounts payables | -12.66 Million | - | - | - | - | 49.62 Million |
| Inventory | -86.26 Million | - | - | - | - | -18.15 Million |
| Other working capital | -3.6 Million | - | - | - | - | -6.44 Million |
| Cash at beginning of period | 370.36 Million | - | - | - | - | 271.06 Million |
| Cash at end of period | 246.55 Million | - | - | - | - | 370.36 Million |
| Capital Expenditure | -44.25 Million | - | - | - | - | -57.04 Million |
| Effect of forex changes on cash | 10.4 Million | - | - | - | - | 21.3 Million |
| Net cash flow / Change in cash | -123.81 Million | - | - | - | - | 99.3 Million |
| Free Cash Flow | -339.48 Million | - | - | - | - | -239.51 Million |
DFM
CAIXY
001560
4893
AIW
0A23